NCT03310632 - Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

November 1, 2023

Study Completion Date

December 31, 2024

Conditions

Pancreatic Neoplasm

Interventions

DRUG

Antroquinonol

Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.

Trial Locations (9)

704

National Cheng Kung University Hospital, Tainan City

3722

Severance Hospital, Seoul

5505

Asan Medical Center, Seoul

10408

National Cancer Center, Goyang-si

11217

Taipei Veterans General Hospital, Taipei

19124

Cancer Treatment Centers of America - Eastern Regional Medical Center, Philadelphia

30265

CTCA Southeastern Regional Medical Center, Newnan

33613

Florida Hospital Tampa, Tampa

48202

Henry Ford Health System, Detroit